Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712490 · ClinicalTrials.gov registry record · Phase 3
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,334
- Enrollment target
NCT01712490: Completed Phase 3 study, sponsored by Takeda.
NCT01712490 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,334 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01712490, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,334 participants
- Enrollment target
Study Summary
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Primary Outcome
mPFS was defined as the time from the date of randomization to the date of the first of documentation of progressive disease (PD), death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for Hodgkin lymphoma (HL) after completion of frontline therapy. PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Frontline therapy is the part of
Interventions
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG vinblastine
- DRUG dacarbazine
- DRUG bleomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,334 participants |
| Start Date | 2012-11-09 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 3 |
What the finished NCT01712490 record still lists
NCT01712490 is an interventional study that assigns participants to a tested intervention. Its 1,334 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 5 interventions - of which doxorubicin is the first listed.
NCT01712490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01712490 about?
NCT01712490 is a clinical study titled "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma". This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtaine...
What is the current status of trial NCT01712490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,334 participants. The study started on 2012-11-09. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT01712490?
The interventions under investigation include: doxorubicin (DRUG), brentuximab vedotin (DRUG), vinblastine (DRUG), dacarbazine (DRUG), bleomycin (DRUG).
Who is sponsoring clinical trial NCT01712490?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01712490's enrollment target sits among peer trials
1,334 183rd of 2000 higher than 1,818 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06972056 · 1,335 participants · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI